Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16

[1]  H. Katus,et al.  Increased plasma concentrations of soluble CD40 ligand in acute coronary syndrome depend on in vitro platelet activation. , 2007, Clinical chemistry.

[2]  G. Lip,et al.  High-Sensitivity C-Reactive Protein and Soluble CD40 Ligand as Indices of Inflammation and Platelet Activation in 880 Patients With Nonvalvular Atrial Fibrillation: Relationship to Stroke Risk Factors, Stroke Risk Stratification Schema, and Prognosis , 2007, Stroke.

[3]  D. Morrow,et al.  Benchmarks for the Assessment of Novel Cardiovascular Biomarkers , 2007, Circulation.

[4]  P. Libby,et al.  Influence of pre-analytical and analytical factors on soluble CD40L measurements. , 2006, Clinical science.

[5]  Peter Libby,et al.  The immune response in atherosclerosis: a double-edged sword , 2006, Nature Reviews Immunology.

[6]  C. Heeschen,et al.  Influence of sample type and storage conditions on soluble CD40 ligand assessment. , 2006, Clinical chemistry.

[7]  C. Eby,et al.  Soluble CD40 ligand measurement inaccuracies attributable to specimen type, processing time, and ELISA method. , 2005, Clinical chemistry.

[8]  Fred S Apple,et al.  Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. , 2005, Clinical chemistry.

[9]  George A Mensah,et al.  CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: overview. , 2004, Circulation.

[10]  G. Hankey,et al.  Measurement of soluble P‐selectin and soluble CD40 ligand in serum and plasma , 2004, Journal of thrombosis and haemostasis : JTH.

[11]  P. Libby,et al.  Effect of Atorvastatin on Risk of Recurrent Cardiovascular Events After an Acute Coronary Syndrome Associated With High Soluble CD40 Ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study , 2004, Circulation.

[12]  L. Horstman,et al.  Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk. , 2004, Thrombosis research.

[13]  P. Libby,et al.  Soluble CD40L: Risk Prediction After Acute Coronary Syndromes , 2003, Circulation.

[14]  N. Kleiman,et al.  Soluble CD40 ligand in acute coronary syndromes. , 2003, The New England journal of medicine.

[15]  D. Bereczki,et al.  Should soluble CD40 ligand be measured from serum or plasma samples? , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[16]  H. Gold,et al.  Cardiopulmonary Bypass Induces Release of Soluble CD40 Ligand , 2002, Circulation.

[17]  P. Libby,et al.  Soluble CD40L and Cardiovascular Risk in Women , 2001, Circulation.

[18]  A. Skene,et al.  Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. , 2000, Circulation.

[19]  K. Forfang,et al.  Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. , 1999, Circulation.

[20]  P. Libby,et al.  CD40 signaling in vascular cells: a key role in atherosclerosis? , 1998, Atherosclerosis.

[21]  Reinhold Förster,et al.  CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells , 1998, Nature.

[22]  P. Libby,et al.  Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.